Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Oxiranecarboxaldehyde, 3-cyclohexyl-, (2S,3R)- (9CI) is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

475056-70-3

Post Buying Request

475056-70-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

475056-70-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 475056-70-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,5,0,5 and 6 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 475056-70:
(8*4)+(7*7)+(6*5)+(5*0)+(4*5)+(3*6)+(2*7)+(1*0)=163
163 % 10 = 3
So 475056-70-3 is a valid CAS Registry Number.

475056-70-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name (2S,3R)-3-cyclohexyloxirane-2-carbaldehyde

1.2 Other means of identification

Product number -
Other names (2S,3R)-3-Cyclohexyl-oxirane-2-carbaldehyde

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:475056-70-3 SDS

475056-70-3Relevant articles and documents

An organocatalytic one-pot cascade incorporating the Achmatowicz reaction affording 3-pyrone derivatives

Ransborg, Lars Krogager,Lykke, Lennart,Hammer, Niels,N?sborg, Line,J?rgensen, Karl Anker

, p. 7604 - 7606 (2014/07/08)

The development of an organocatalytic one-pot cascade for the annulation of simple starting materials: α,β-unsaturated aldehydes, hydrogen peroxide, β-carbonyl compounds and NBS to furnish optically active 3-pyrones in good yield and with excellent enanti

Spirodiketopiperazine-based CCR5 antagonist: Discovery of an antiretroviral drug candidate

Nishizawa, Rena,Nishiyama, Toshihiko,Hisaichi, Katsuya,Minamoto, Chiaki,Matsunaga, Naoki,Takaoka, Yoshikazu,Nakai, Hisao,Jenkinson, Stephen,Kazmierski, Wieslaw M.,Tada, Hideaki,Sagawa, Kenji,Shibayama, Shiro,Fukushima, Daikichi,Maeda, Kenji,Mitsuya, Hiroaki

, p. 1141 - 1145 (2011/04/16)

Following the discovery that hydroxylated derivative 3 (Fig. 1) was one of the oxidative metabolites of the original lead 1, it was found that hydroxylated compound 4 possesses higher in vitro anti-HIV potency than the corresponding non-hydroxylated compo

Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5- dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: A highly potent orally available CCR5 selective antagonist

Nishizawa, Rena,Nishiyama, Toshihiko,Hisaichi, Katsuya,Minamoto, Chiaki,Murota, Masayuki,Takaoka, Yoshikazu,Nakai, Hisao,Tada, Hideaki,Sagawa, Kenji,Shibayama, Shiro,Fukushima, Daikichi,Maeda, Kenji,Mitsuya, Hiroaki

, p. 4028 - 4042 (2011/08/21)

Based on the original spirodiketopiperazine design framework, further optimization of an orally available CCR5 antagonist was undertaken. Structural hybridization of the hydroxylated analog 4 derived from one of the oxidative metabolites and the new orally available non-hydroxylated benzoic acid analog 5 resulted in another potent orally available CCR5 antagonist 6a as a clinical candidate. Full details of a structure-activity relationship (SAR) study and ADME properties are presented.

Enantioselective organocatalytic epoxidation using hypervalent iodine reagents

Lee, Sandra,MacMillan, David W.C.

, p. 11413 - 11424 (2007/10/03)

A rare example of a hypervalent iodine reagent participating in a 1,4-heteroconjugate addition reaction is reported for the organocatalytic, asymmetric epoxidation of α,β-unsaturated aldehydes using imidazolidinone catalyst 1. Development of an 'internal syringe pump' effect via the slow release of iodosobenzene from an iminoiodinane source provides high levels of reaction efficiency and enantiomeric control in the asymmetric epoxidation of electron-deficient olefins. 15N NMR studies were conducted to elucidate the reaction pathways that lead to catalyst depletion in the presence of prototypical oxidants. These NMR studies also provided the mechanistic foundation for the application of iminoiodinanes as an internal slow release oxidant to circumvent these catalyst depletion pathways.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 475056-70-3